

Aerie Pharmaceuticals Investor Relations Department 135 US Highway 206, Suite 15 Bedminster, NJ 07921 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: AERI Last Trade: 53.05 Trade Time: 4:00 PM ET Aug 18, 2017 -1.75 🖶 (-Change: 3.193%) Day Range 52.95 - 55.50 52-Week 18.52 - 59.50 Range Volume 389,629


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-inclass therapies for the treatment of patients with glaucoma and other diseases of the eye.

Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, RhopressaTM (netarsudi... (more)

Stock Performance



Press Releases [View all]

Aug 14, 2017

Aerie Pharmaceuticals Announces
Appointment of Isabel Moredo, PharmD, as
Eastern Regional Director of Medical Science
Liaisons

Aug 8, 2017

Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer

Aug 2, 2017

Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference

Aug 1, 2017

Aerie Pharmaceuticals Reports Second
Quarter 2017 Financial Results and Provides
Business Update

Jul 31, 2017

Aerie Pharmaceuticals Enters into
Collaboration Agreement with DSM Focused
on Technology to Potentially Deliver Aerie
Compounds to Treat Retinal Diseases such
as Wet AMD

Financials [View all]

Second Quarter Financial Results

Mar 9, 2017

Annual Report (10-K)

Apr 27, 2017

Proxy Statement (DEF 14A)

Aug 3, 2017

Quarterly Report (10-Q)

May 3, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)